You are here

Craig Strathdee


Bregman H, Chakka N, Guzman-Perez A, et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem. 2013;56:4320–4342.

Lippa MS, Strockbine LD, Le TT, et al. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis. 2007;12:1465–1478.

Brown CY, Sadlon T, Gargett T, et al. Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector. Hum Gene Ther. 2010;21:1005–1017.

Craig Strathdee, Ph.D.

Craig Strathdee is a senior group leader in the Cancer Program at the Broad Institute of MIT and Harvard. Under the direction of Matthew Meyerson, Strathdee leads a group responsible for validating and prosecuting drug targets that have emerged from the Broad Institute's comprehensive oncogenomics efforts. The approach to target validation utilizes RNAi, CRISPR, and ORF expression platforms to genetically perturb candidate target gene expression in relevant cancer cell lines, and then profile the resulting phenotypic changes with regard to their effect on various biochemical pathways. Strathdee's group is responsible for the identification and implementation of suitable cell-based screens to support the subsequent HTS, and it is also actively contributing to the design of a suitable assay cascade to support the follow-on hit expansion and lead optimization efforts.

Strathdee joined the Broad Institute in 2013 after working at the Ontario Institute for Cancer Research as a senior biologist and group leader. He gained extensive experience in industry working as a research scientist/director at Amgen for 11 years, prior to which he worked in academic research as an assistant professor/principal investigator at the University of Western Ontario/Robarts Research Institute. He also has public health experience via a 2-year tenure as a research scientist with Canada's Laboratory Centre for Disease Control.  

Strathdee earned his Ph.D. in microbial pathogenesis and B.Sc. in microbiology from the University of Guelph. His postdoctoral fellowship in human genetics was undertaken at the Hospital for Sick Children/University of Toronto.

Contact Craig Strathdee at

January 2017